27 research outputs found

    Tobramycin pharmacokinetics in continuous ambulatory peritoneal dialysis (CAPD)

    No full text
    ์˜ํ•™๊ณผ/์„์‚ฌ[ํ•œ๊ธ€]๊ณ„์†์  ์™ธ๋ž˜ ๋ณต๊ฐ•๊ด€๋ฅ˜(Continuous Ambulatory Peritoneal Dialysis : CAPL)๋Š” ๋„“์€ ๋ณต๋ง‰๋ฉด์— ๊ด€๋ฅ˜์•ก์ด ๊ณ„์† ์ ‘์ด‰ํ•˜์—ฌ ์šฉ์งˆ๊ณผ ์ˆ˜๋ถ„๊ตํ™˜์— ํšจ๊ณผ์ ์ด์ง€๋งŒ ์ค‘๋…ํ•œ ํ•ฉ๋ณ‘์ฆ์œผ๋กœ ๋ณต๋ง‰์—ผ์ด ์ˆ˜๋ฐ˜๋  ์ˆ˜ ์žˆ๋‹ค. ๋ณธ ๊ด€์ฐฐ์€ CAPD ํ™˜์ž์—์„œ ๋ฐœ์ƒํ•˜๋Š” ๋ณต๋ง‰์—ผ๊ณผ ์ „์‹ ๊ฐ์—ผ์„ ํ•ญ๊ท ์ œ ํˆฌ์—ฌ๋กœ ์น˜๋ฃŒํ•˜๋Š”๋ฐ ์žˆ์–ด์„œ ํŠนํžˆ tobyamycin์˜ ๋…์„ฑ์„ ์ตœ์†Œํ•œ๋„๋กœ ์ค„์ผ ์ˆ˜ ์žˆ๋Š” ํˆฌ์—ฌ๊ฒฝ๋กœ์™€ ์šฉ๋Ÿ‰๊ฒฐ์ •์— ์ค‘์ ์„ ๋‘์—ˆ๋‹ค. ๋Œ€์ƒ์€ ๋ณต๋ง‰์—ผ์ด ๋™๋ฐ˜๋˜๊ฑฐ๋‚˜ ๋™๋ฐ˜๋˜์ง€ ์•Š์€ CAPD ํ™˜์ž 20๋ช…์„ ์„ ํƒํ•˜์—ฌ ๊ณ„์†์  ์ฃผ์ž… ๋˜๋Š” ๊ฐ„ํ—์  ์ฃผ์ž…์œผ๋กœ ๋ณต๊ฐ•๋‚ด tobramycin์„ ํˆฌ์—ฌํ•˜๋ฉด์„œ ์•ฝ์—ญํ•™์  ๊ด€์ฐฐ์— ์น˜์ค‘ํ•˜์—ฌ ๋‹ค์Œ๊ณผ ๊ฐ™์€ ๊ฒฐ๊ณผ๋ฅผ ์–ป์—ˆ๋‹ค. 1. ๋ณต๊ฐ•๊ด€๋ฅ˜๋ฅผ ํ†ตํ•˜์—ฌ tobramycin 10mg์„ ๊ด€๋ฅ˜์•ก 2โ„“์— ๊ณ„์†์ ์œผ๋กœ ๊ด€๋ฅ˜ํ•  ๋•Œ 6์‹œ๊ฐ„ํ›„ ๊ด€๋ฅ˜์•ก๋‚ด tobramycin ๋†๋„๋Š” ๋ณต๋ง‰์—ผ์ด ์žˆ์„ ๋•Œ 1.81ยฑ0.22ใŽ/ml์˜€๊ณ , ๋ณต๋ง‰์—ผ์ด ์—†์„ ๋•Œ 2.52ยฑ0.20 ใŽ/ml์˜€์œผ๋ฉฐ 6์‹œ๊ฐ„ ๋ณต๋ง‰์„ ํ†ตํ•œ toramycin ํก์ˆ˜์œจ์€ ๊ฐ๊ฐ 66.2ยฑ2.4, 47.7ยฑ5. 4% ๋ณต๋ง‰์—ผ์ด ์žˆ์„ ๋•Œ tobramycin์˜ ํก์ˆ˜์šธ์€ ์œ ์˜ํ•˜๊ฒŒ ์ฆ๊ฐ€ํ•˜์˜€๋‹ค. 2. ๋ณต๋ง‰์—ผ ํ•ฉ๋ณ‘์œ ๋ฌด์— ๋ถˆ๊ตฌํ•˜๊ณ  ๊ด€๋ฅ˜์•ก 2โ„“์— obramycin์˜ ๋†๋„๋Š” ์œ ์˜ํ•œ ์ฐจ์ด๊ฐ€ ์—†๊ณ , ๋˜ํ•œ ์ถ”์ ๊ฒ€์‚ฌ ๊ธฐ๊ฐ„๋™์•ˆ ํ˜ˆ์ฒญ tobramycin ๋†๋„๋Š” ์ผ์ •ํ•˜๊ฒŒ ์œ ์ง€๋˜์—ˆ๋‹ค. 3. ๋ณต๊ฐ•๊ด€๋ฅ˜๋ฅผ ํ†ตํ•˜์—ฌ tobrmycin 1.8mg/kg์„ ํˆฌ์—ฌํ•˜๋ฉด ๋ณต๋ง‰์—ผ์˜ ์œ ๋ฌด์— ๋”ฐ๋ผ 6์‹œ๊ฐ„ํ›„ 2โ„“์˜ ๊ด€๋ฅ˜์•ก๋‚ด์˜ tobramycin ๋†๋„๋Š” ๊ฐ๊ฐ 2.52ยฑ0.18 ใŽ/ml ๋ฐ 4.31ยฑ0.29 ใŽ/ml์ด๊ณ  6์‹œ๊ฐ„๋™์•ˆ ๋ณต๋ง‰์„ ํ†ตํ•œ tobramycin์˜ ํก์ˆ˜์œจ์€ ๊ฐ๊ฐ 70.8ยฑ2.5, 48.2ยฑ4.8%๋กœ ๋ณต๋ง‰์—ผ์ด ์žˆ์„ ๋•Œ ์œ ์˜ํ•˜๊ฒŒ ์ฆ๊ฐ€ํ•˜์˜€๋‹ค. 4. ๋ณต๋ง‰์—ผ ํ•ฉ๋ณ‘์œ ๋ฌด์— ๋ถˆ๊ตฌํ•˜๊ณ  ๊ด€๋ฅ˜์•ก์•  tobramycin 1.0 mg/kg์˜ ๊ฐ„ํ—์  ํˆฌ์—ฌ๋กœ 6์‹œ๊ฐ„ํ›„ ํ˜ˆ์ฒญ tobramycin ๋†๋™ (์ตœ๊ณ  ํ˜ˆ์ฒญ๋†๋„)์— ํฐ ์ฐจ์ด๊ฐ€ ์—†๊ณ , 48์‹œ๊ฐ„ํ›„์˜ ํ˜ˆ์ฒญ tobramycin ๋†๋„(์ตœ์ € ํ˜ˆ์ฒญ๋†๋„)๋„ ์ฐจ์ด๊ฐ€ ์—†์—ˆ๋‹ค. 5. ๋ณต๊ฐ• ๊ด€๋ฅ˜์•ก 2โ„“์— tobramycin์„ ๊ณ„์†์ ์œผ๋กœ 10mg ํ˜น์€ ๊ฐ„ํ—์ ์œผ๋กœ 1.0mg/kg์œผ๋กœ ํˆฌ์—ฌํ•˜๊ณ  ํ˜ˆ์ฒญ๋†๋„๋ฅผ 13์ผ๊นŒ์ง€ ์ถ”์ ํ•œ ๋ฐ” ๊ณ„์† ํ•ญ๊ท ๋†๋„๋ฅผ ์œ ์ง€ํ•จ์„ ๊ด€์ฐฐํ•˜์˜€๋‹ค. ์ด์ƒ ์„ฑ์ ์œผ๋กœ ๋ณด์•„ ๊ฐ„ํ—์  ํˆฌ์—ฌ์— ์žˆ์–ด์„œ tobramycin ์ดˆ๊ธฐ์šฉ๋Ÿ‰์€ 1.8mg/kg, ์œ ์ง€์šฉ๋Ÿ‰์€ 48์‹œ๊ฐ„๋งˆ๋‹ค 1.0 mg/kg์ด ์ ์ •์šฉ๋Ÿ‰์œผ๋กœ ์ƒ๊ฐ๋˜๋ฉฐ, ๊ณ„์†์  ํˆฌ์—ฌ์—์„œ๋Š” ๋งค ๊ตํ™˜์‹œ tobramycin 2.02โˆผ0.3 mg/kg์ด ํ•„์š”ํ•˜๋‹ค๊ณ  ์ƒ๊ฐ๋œ๋‹ค. ๋˜ CAPD ํ™˜์ž์—์„œ ๋ณต๋ง‰์—ผ ์ด์™ธ์˜ ๊ฐ์—ผ์ฆ์„ ๋™๋ฐ˜ํ•œ ํ™˜์ž์—์„œ๋Š” ๊ณ„์†์  ํˆฌ์—ฌ๊ฐ€ ์ ํ•ฉํ•˜๋‹ค๊ณ  ์ƒ๊ฐ๋œ๋‹ค. [์˜๋ฌธ]To establish guide-lines for methods and dosages of antibiotics in the treatment of CAPL-associated peritonitis by continuous method or pulse method, into 10 patients 96 without and 4 with peritonitis) TBM 10 mg or 0.2 mg/kg was administered every 6 hours mixed in 2โ„“ of dialysate (continuous method )and the other 10 patients (6 without and 4 with peritonitis) was received TBM 1.8 mg/kg as loading dose followed by 1.0 mg/kg every 48 hours (pulse method) Dialysate and serum samples were obtained before and 0.25, 0.5, 1, 2, 4, and 6 hours after TBM administration and thereafter serum samples were obtained every 24 hours up to 13days after first dose of TBM. All samples were frozen at -70 C until TBM concentrations were measured by radioimmunoassay. The results are as follows. 1. By continuous method, dialysate TBM concentrations at 6 hours after administration was significantly lower in patients with peritonitis (1.8ยฑ0.22ug/ml) than in patients without peritonitis (2.52ยฑ0.20 ug/ml), and transperitoneal TBM absorption for 6 hours was significantly higher in patients with peritonitis (66.2ยฑ2.4%) than in patients without peritonitis (47.7ยฑ5.4%) 2. By pulse method, dialysate TBM concentration at 6 hours after administration was significantly lower in patients with peritonitis (2.52ยฑ0.118 ug/ml) than in patients without peritonitis (4.31ยฑ0.29 ug/ml) and transperitoneal TBM absorpiton for 6 hours was significatly higher in patients with peritonitis (70.8ยฑ2.5%) than in patients without pertionitis (48.2ยฑ4.8%) 3. Adequate and similar serum levels of TBM were achieved regardless of peritonitis by both methods of intraperitoneal TBM administration. These results suggest that the continuous method 0.2-0,3 mg/kg of tobramycin intraperitoneally every 6 hours, is useful for the treatment of CAPD associated peritonitis and that the pulse method with 1.8 mg/kg as a loading dose followed by 1.0mg/kg every 48 hours may be adequate for the treatment of infections other than peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients.restrictio

    Microshase alloy

    No full text
    Maste

    Three dimensional analysis of orthodontic tooth movement after extraction of first premolar

    No full text
    ์น˜์˜ํ•™๊ณผ/์„์‚ฌํ˜„์žฌ ๋””์ง€ํ„ธ ์Šค์บ”๋œ ๋ชจํ˜•์„ ๊ฐ€์ง€๊ณ  ์ง„๋‹จ setup์„ ํ•˜๋Š” ์—ฌ๋Ÿฌ ๋ฐฉ๋ฒ•์ด ์†Œ๊ฐœ๋˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ตœ๊ทผ ๊ต์ • ์˜์—ญ์—์„œ ์‚ผ์ฐจ์› ์ง„๋‹จ ํ”„๋กœ๊ทธ๋žจ์˜ ๋ฐœ๋‹ฌ๋กœ ์น˜๋ฃŒ ์ „ํ›„ ๋ชจํ˜• ์ค‘์ฒฉ์„ ํ†ตํ•œ ์น˜์—ด๊ถ ํญ์ด๋‚˜ ๋„“์ด, ์น˜์•„ ์ด๋™์˜ ์–‘์ƒ์— ๊ด€ํ•œ ์—ฐ๊ตฌ๊ฐ€ ์ง„ํ–‰๋˜๊ณ  ์žˆ๋‹ค. ์ด์— ๋ณธ ๋…ผ๋ฌธ์—์„œ๋Š” ์ƒํ•˜์•… ์ œ1 ์†Œ๊ตฌ์น˜ ๋ฐœ์น˜ ํ›„ ์น˜์•„ ๊ต์ • ์ „๊ณผ ํ›„์˜ ์น˜์•„ ๋ชจํ˜•์„ laser scanํ•˜์—ฌ ๋งŒ๋“  digital model์„ ์ค‘์ฒฉํ•˜์—ฌ ๊ฐœ๋ณ„ ์น˜์•„์˜ ์ด๋™ ํŒจํ„ด์„ ๋ถ„์„ํ•˜๊ณ  ์•…๊ถ ๋ชจ์–‘์˜ ๋ณ€ํ™”๋ฅผ ํŒŒ์•…ํ•จ์œผ๋กœ์จ, ์ด๋ฅผ ํ†ตํ•ด ์ง„๋‹จ setup์‹œ ํ•„์š”ํ•œ ๊ฐ€์ด๋“œ๋ผ์ธ์„ ์ œ์‹œํ•  ์ˆ˜ ์žˆ๊ณ  ๊ต์ • ๋ฐ ์„ ์ˆ˜์ˆ  ์น˜๋ฃŒ ๊ณ„ํš์„ ์ˆ˜๋ฆฝ์— ๋„์›€์ด ๋˜๊ณ ์ž ํ•˜์˜€๋‹ค. 1.์น˜์•„์˜ ์—ฌ๋Ÿฌ ๊ธฐ์ค€์ ๊ณผ ์ด๋“ค์„ ์ด์šฉํ•œ ์น˜๊ด€์˜ ๊ทผ-์›์‹ฌ๊ณผ ํ˜‘-์„ค์ธก ์น˜๊ด€ ํ‰๋ฉด, ์ˆ˜ํ‰๊ณผ ๊ด€์ƒ ๋ฐ ์‹œ์ƒ ๊ธฐ์ค€ํ‰๋ฉด, ๋“ฑ์„ ์ƒˆ๋กญ๊ฒŒ ์ •์˜ํ•˜๊ณ  ์ด์šฉํ•˜์˜€์œผ๋ฉฐ ์•ˆ์ •์ ์ž„์„ ํ™•์ธํ•˜์˜€๋‹ค. ์ƒ์•… ๋ชจํ˜•๊ณผ ๋งž๋ฌผ๋ฆฐ ํ•˜์•… ๋ชจํ˜•์„ ์Šค์บ”ํ•œ ๋’ค ์ƒ์•… ๋ชจํ˜•์„ ์ค‘์ฒฉ ๊ธฐ์ค€์œผ๋กœ ์ด์šฉํ•ด ํ•˜์•… ๋ชจํ˜•์˜ ๊ต์ • ์ „-ํ›„ ๋ณ€ํ™”๋ฅผ ์ถ”์ ํ•  ์ˆ˜ ์žˆ์—ˆ๋‹ค. 2.์น˜์•„์˜ ์œ„์น˜ ๋ฐ ๊ฐ๋„์˜ 3์ฐจ์› ๋ณ€ํ™”๋ฅผ 3D measurement์™€ projected measurement๋กœ ๊ตฌ๋ถ„ํ•˜์—ฌ ์ธก์ •ํ•˜์˜€๊ณ , ๊ทธ ๊ฒฐ๊ณผ๋ฅผ ๋น„๊ตํ•˜์—ฌ ์ฐจ์ด๋ฅผ ํ™•์ธํ•˜์˜€๋‹ค. 3.์ œ1 ์†Œ๊ตฌ์น˜ ๋ฐœ์น˜ ํ›„ ์ƒ์•… ์ „์น˜๋ถ€(์ค‘์ ˆ์น˜, ์ธก์ ˆ์น˜, ๊ฒฌ์น˜)๋Š” ๊ตฌ๊ฐœ์ธก์œผ๋กœ ๊ธฐ์šธ์–ด์กŒ์œผ๋ฉฐ ์ค‘์ ˆ์น˜๊ฐ€ ๊ฐ€์žฅ ํฌ๊ฒŒ ๊ธฐ์šธ์—ˆ๊ณ , ๊ตฌ์น˜๋ถ€(์ œ2์†Œ๊ตฌ์น˜, ์ œ1๋Œ€๊ตฌ์น˜)๋Š” ํ˜‘์ธก์œผ๋กœ ๊ธฐ์šธ์–ด์กŒ๋‹ค. ํ•˜์•…์—์„œ๋Š” ์ „์น˜๋ถ€๊ฐ€ ์ƒ์•…๊ณผ ๋น„์Šทํ•œ ๋ณ€ํ™”๋ฅผ ๋ณด์ธ๋ฐ ๋ฐ˜ํ•˜์—ฌ ๊ตฌ์น˜๋ถ€๋Š” ์„ค์ธก์œผ๋กœ ๊ธฐ์šธ์–ด์กŒ๋‹ค. ์ด์— ๋”ฐ๋ผ ์•…๊ถํ˜•ํƒœ๋Š” V ํ˜•ํƒœ์—์„œ U ํ˜•ํƒœ๋กœ ๋ณ€ํ™”ํ•˜์˜€๊ณ , curve of Spee๋Š” ๊ฐ์†Œํ•˜์˜€๋‹ค.4.์ƒ์•… ์ธก์ ˆ์น˜ ๋ฐ ๊ฒฌ์น˜๋Š” ์ œ1์†Œ๊ตฌ์น˜ ๋ฐœ์น˜์™€ ๊ณต๊ฐ„์œผ๋กœ์˜ ์›์‹ฌ ํšŒ์ „, ์ œ2์†Œ๊ตฌ์น˜ ๋ฐ ์ œ2๋Œ€๊ตฌ์น˜๋Š” ๊ทผ์‹ฌ ํšŒ์ „์„ ๋ณด์˜€๋‹ค. ํ•˜์•…์—์„œ๋„ ๋น„์Šทํ•˜๊ฒŒ ์ธก์ ˆ์น˜์˜ ์›์‹ฌ ํšŒ์ „, ์ œ2์†Œ๊ตฌ์น˜์˜ ๊ทผ์‹ฌ ํšŒ์ „์„ ํ™•์ธํ•˜์˜€๋‹ค.5.์ƒ์•…์—์„œ ์ค‘์ ˆ์น˜, ์ธก์ ˆ์น˜, ์ œ1๋Œ€๊ตฌ์น˜, ์ œ2๋Œ€๊ตฌ์น˜๊ฐ€ ๋งน์ถœ๋˜์—ˆ์œผ๋ฉฐ ์ œ2์†Œ๊ตฌ์น˜๋Š” ํ•จ์ž…๋˜์—ˆ๋‹ค. ํ•˜์•…์—์„œ๋Š” ์ œ2๋Œ€๊ตฌ์น˜๊ฐ€ ํ•จ์ž…๋˜์—ˆ๋‹ค.๋ณธ ์—ฐ๊ตฌ์—์„œ ์ œ1 ์†Œ๊ตฌ์น˜ ๋ฐœ์น˜๋ฅผ ํ†ตํ•œ ๊ต์ •์ „ ๋ชจ๋ธ๊ณผ ๊ต์ •ํ›„ ๋ชจ๋ธ์˜ ๊ตฌ๊ฐœ๋ถ€ ์ค‘์ฒฉ์„ ํ†ตํ•ด ๊ต์ • ์น˜์•„์ด๋™ ํŒจํ„ด์„ ํŒŒ์•…ํ•˜์—ฌ ์ง„๋‹จ setup์„ ์‹œํ–‰ํ•  ๋•Œ ํ•„์š”ํ•œ ์น˜์•„ ์œ„์น˜์— ๋Œ€ํ•œ ์ •๋ณด๋ฅผ ์–ป์„ ์ˆ˜ ์žˆ์—ˆ๋‹ค.ope

    ํ๋‹จ๋ฉด ๋ฐ•ํŒ๋ณด์˜ ๋น„ํ‹€๋ฆผ, ๋””์Šคํ† ์…˜, ์›Œํ•‘ ๋ฌธ์ œ๋ฅผ ์œ„ํ•œ 1์ฐจ์› ํ•ด์„

    No full text
    Thesis (doctoral)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :๊ธฐ๊ณ„์„ค๊ณ„ํ•™๊ณผ,1999.Docto

    Preparation and Permeation Properties of Cellulose acetate Forward Osmosis Membrane

    No full text
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ๋ฐ”์ด์˜ค์‹œ์Šคํ…œ.์†Œ์žฌํ•™๋ถ€(๋ฐ”์ด์˜ค์†Œ์žฌ๊ณตํ•™์ „๊ณต), 2011.2. ํƒํƒœ๋ฌธ.Maste

    Ribotyping of porphyromonas gingivalis isolated from rapidly progressive periodontitis patients

    No full text
    ์น˜์˜ํ•™๊ณผ/๋ฐ•์‚ฌ[ํ•œ๊ธ€] ๋ณธ ์—ฐ๊ตฌ์—์„œ๋Š” ํ•œ๊ตญ์ธ์˜ ๊ธ‰์†์ง„ํ–‰์„ฑ ์น˜์ฃผ์—ผ ํ™˜์ž๋กœ๋ถ€ํ„ฐ ๋ถ„๋ฆฌํ•œ Porphyromonas gingivalis(P. gingvalis)๋ฅผ ribotyping ๋ฐฉ๋ฒ•์„ ํ†ตํ•ด ํ•œ๊ตญ์ธ์—์„œ ์–ด๋–ค ribotype์ด์žˆ๋Š”์ง€, ๋˜ํ•œ ๊ฐ ํ™˜์ž์˜ .p. gingivalis ์‚ฌ์ด์— ์œ ์ „์  ์ด์งˆ์„ฑ์ด ์กด์žฌํ•˜๋Š”์ง€๋ฅผ 16S rRNA์— ์˜๊ฑฐํ•œ ์˜ฌ๋ฆฌ๊ณ  ๋‰ดํด๋ ˆ์˜คํƒ€์ด๋“œ ์†Œ์‹์ž๋ฅผ ์ด์šฉํ•˜์—ฌ ๊ทœ๋ช…ํ•˜๊ณ  ๊ฐ ribotype์— ๋”ฐ๋ผ fimbrillin์— ๋Œ€ํ•œ ํ•ญ์›์  ์ด์งˆ์„ฑ๊ณผ ๋‹จ๋ฐฑ๋ถ„ํ•ดํ™œ์„ฑ๋„๋ฅผ ๋ถ„์„ํ•œ ๊ฒฐ๊ณผ ๋‹ค์Œ๊ณผ ๊ฐ™์€ ๊ฒฐ๊ณผ๋ฅผ ์–ป์—ˆ๋‹ค. 1. ์ œํ•œํšจ์†Œ Kpal ๋ฐ .Pstโ… ์„ ์‚ฌ์šฉํ•˜์—ฌ P. gingivalis๋ฅผ ribotypingํ•œ ๊ฒฐ๊ณผ ๊ฐ๊ฐ 6ํ˜•๊ณผ 7ํ˜•์˜ ๋‹ค๋ฅธ ribotype์ด ํ™•์ธ๋˜์—ˆ๋‹ค. Kpnโ…  ์‚ฌ์šฉ์‹œ ๋‚˜ํƒ€๋‚œ ribotype์„ ๊ธฐ์ค€ํ˜•์œผ๋กœ ์ •ํ•˜๊ณ  Pstโ…  ์‚ฌ์šฉ์‹œ ์„ธ๋ถ„๋œ ํ˜•์„ ํ•ฉํ•˜์—ฌ ์ด 8ํ˜•์˜ ribotype์„ ๊ด€์ฐฐํ•  ์ˆ˜์žˆ์—ˆ๋‹ค. 2. Ribotype โ… /eํ˜•์ด ๊ฐ€์žฅ ๋นˆ๋„์ˆ˜๊ฐ€ ๋†’์•˜๋‹ค. 3. ๋ฐฐ์–‘๋ถ„๋ฆฌ๋œ P.gingvalis ๊ท ์ฃผ์—์„œ ๋ฐœํ˜„๋œ fimbrillin์€ 41kDa, 43kDa, 49KkDa์˜ ํฌ๊ธฐ๋ฅผ ๋ณด์˜€๋‹ค. 4. P. gingivalis ๊ท ์ฃผ๋Š” ๋ชจ๋‘ ๊ฐ•ํ•œ ๋‹จ๋ฐฑ๋ถ„ํ•ด ํšจ์†Œ๋Šฅ์„ ๋‚˜ํƒ€๋‚ด์—ˆ๋‹ค.์ด์ƒ์˜ ๊ฒฐ๋ก ์—์„œ 10๋ช…์˜ ๊ธ‰์†์ง„ํ–‰์„ฑ ์น˜์ฃผ์—ผํ™˜์ž๋กœ ๋ถ€ํ„ฐ ์ฑ„์ทจํ•œ P.gingivalis ๊ท ์ฃผ๋ฅผ 16S rRNA์— ์˜๊ฑฐํ•œ ์˜ฌ๋ฆฌ๊ณ ๋‰ดํด๋ ˆ์˜คํƒ€์ด๋“œ ์†Œ์‹์ž๋กœ ribotypingํ•œ ๊ฒฐ๊ณผ ๊ฐ€์žฅ๋งŽ์ด ๋ณด์œ ํ•œ ribotype์€ โ… /eํ˜•์œผ๋กœ์„œ ํ™˜์ž์˜ 40%๋ฅผ ์ฐจ์ง€ํ•˜์˜€๊ณ  ๋˜ํ•œ ํ•œ ๊ฐœ์ธ์ด ๋‘๊ฐœ์˜ ribotype์„ ๋ณด์œ ํ•  ์ˆ˜์žˆ์Œ์„ ํ™•์ธํ•  ์ˆ˜ ์žˆ์—ˆ๋‹ค. [์˜๋ฌธ] This study examined ribotypes of 36 P. gingivalis strains isolated from 10rapidly progressive periodontitis patients in Korean and revealed the presence of genetic heterogeneity among the patients. Ribotyping was performed by using a oligonucleotide probes based on 165 rRNA after whole genomic DNA had been digested with the restriction endonuclease enzyme Kpnโ…  and Pstโ… . In addition, the antigenic heterogeneity of fimbrillin and pretense activity was analysed to observe the virulency of P. gingivalis. The results were as follows. 1. Using Kpnโ… , 6 ribotypes were detected, whereas 7 ribotypes were identifiedby using Pstโ… . When combined two enzymes, a total of 8 ribotypes were subgrouped. 2. Ribotype I /e was the most common and detected in 4 among 10 patients. 3. The fimbrillin expressed from P. gingvalis isolates had the molecular size of 41kDa, 43kDa, 49kDa. It was observed that the size of fimbrillin with the same ribotypes could be identical. 4. All the P. gingivalis strains showed strong proteolytic activity In summary, total 8 ribotypes were observed for isolates from rapidly progressive periodontitis patients. Forty percent of the patients harbored isolates exhibiting the same ribotype I /e, and it was obseryed that more than one ribotype can coexist in an individual patient.ope

    ์„œ์šธ๊ถŒ์—ญ ํ•˜์ฒœ ๋‘”์น˜์˜ ๋ฐ”๋žŒ์งํ•œ ์ด์šฉ๊ณผ ๋ณด์ „ ๋ฐฉ์•ˆ

    No full text
    ๋…ธํŠธ : ์ด ๋ณด๊ณ ์„œ์˜ ๋‚ด์šฉ์€ ์—ฐ๊ตฌ์ง„์˜ ๊ฒฌํ•ด๋กœ์„œ ์„œ์šธํŠน๋ณ„์‹œ์˜ ์ •์ฑ…๊ณผ๋Š” ๋‹ค๋ฅผ ์ˆ˜๋„ ์žˆ์Šต๋‹ˆ๋‹ค

    ๋‹ค๋…„๋„ ์˜ˆ์‚ฐํšŒ๊ณ„๋…„๋„์ œ๋„ ๋„์ž…๊ตฌ์ƒ์— ๊ด€ํ•œ ์—ฐ๊ตฌ : ๊ตญ๋ฐฉ๋ถ€๋ฌธ ๋ฐฉ์œ„๋ ฅ ๊ฐœ์„ ์‚ฌ์—…์„ ์ค‘์‹ฌ์œผ๋กœ

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ํ–‰์ •๋Œ€ํ•™์› :ํ–‰์ •ํ•™๊ณผ ์ •์ฑ…ํ•™์ „๊ณต,1998.Maste
    corecore